X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
incb018424 (56) 56
index medicus (56) 56
humans (52) 52
myelofibrosis (31) 31
ruxolitinib (30) 30
oncology (29) 29
janus kinase 2 - antagonists & inhibitors (25) 25
myeloproliferative neoplasms (22) 22
primary myelofibrosis - drug therapy (22) 22
janus kinase 1 - antagonists & inhibitors (21) 21
pharmacology & pharmacy (21) 21
pyrazoles - therapeutic use (20) 20
hematology (18) 18
incb018424 phosphate (18) 18
pharmacokinetics (18) 18
polycythemia-vera (18) 18
pyrazoles - adverse effects (18) 18
drug therapy (16) 16
female (16) 16
inhibitor (16) 16
male (16) 16
mutation (16) 16
jak2 inhibitor (15) 15
janus kinases - antagonists & inhibitors (15) 15
protein kinase inhibitors - therapeutic use (15) 15
pyrazoles - pharmacology (15) 15
safety (15) 15
animals (14) 14
treatment outcome (14) 14
efficacy (13) 13
essential thrombocythemia (13) 13
pyrazoles - pharmacokinetics (13) 13
tyrosine kinase jak2 (13) 13
research (12) 12
middle aged (11) 11
myeloid metaplasia (11) 11
adult (10) 10
available therapy (10) 10
myeloproliferative disorders (10) 10
pyrazoles - administration & dosage (10) 10
survival (10) 10
article (9) 9
cancer (9) 9
international working group (9) 9
leukemia (9) 9
pharmacodynamics (9) 9
primary myelofibrosis (9) 9
protein kinase inhibitors - pharmacology (9) 9
abridged index medicus (8) 8
aged (8) 8
care and treatment (8) 8
janus kinase (8) 8
therapy (8) 8
activation (7) 7
antineoplastic agents - pharmacology (7) 7
clinical trials as topic (7) 7
jak inhibitor (7) 7
jak2 (7) 7
quality of life (7) 7
signal transduction - drug effects (7) 7
splenomegaly (7) 7
analysis (6) 6
anemia (6) 6
dose-response relationship, drug (6) 6
double-blind (6) 6
double-blind method (6) 6
international-working-group (6) 6
janus kinase 2 (6) 6
medicine & public health (6) 6
mice (6) 6
myeloproliferative neoplasm (6) 6
primary myelofibrosis - pathology (6) 6
protein kinase inhibitors - adverse effects (6) 6
tumors (6) 6
young adult (6) 6
activating mutation (5) 5
aged, 80 and over (5) 5
criteria (5) 5
development and progression (5) 5
dosage and administration (5) 5
drugs (5) 5
expression (5) 5
follow-up studies (5) 5
hemic and lymphatic diseases (5) 5
internal medicine (5) 5
janus kinase 2 - genetics (5) 5
management (5) 5
neoplasms (5) 5
pathogenesis (5) 5
polycythemia vera (5) 5
polycythemia vera - drug therapy (5) 5
primary myelofibrosis - genetics (5) 5
progenitor cells (5) 5
quality-of-life (5) 5
spleen (5) 5
spleen - pathology (5) 5
toxicology (5) 5
adolescent (4) 4
anemia - chemically induced (4) 4
antineoplastic agents - adverse effects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 11/2013, Volume 19, Issue 22, pp. 6230 - 6241
Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of... 
PATHOGENESIS | MURINE MODEL | POLYCYTHEMIA-VERA | JAK2 INHIBITOR | ONCOLOGY | PHASE-II | INCB018424 | MUTATIONS | THROMBOCYTHEMIA | PRIMARY MYELOFIBROSIS | PANOBINOSTAT
Journal Article
Nature medicine, ISSN 1078-8956, 2014, Volume 20, Issue 9, pp. 1043 - 1049
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Journal Article
Journal Article
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, ISSN 1083-8791, 9/2014, Volume 20, Issue 9, pp. 1274 - 1281
Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis collectively referred to as myeloproliferative neoplasms (MPN). Allogeneic... 
INCB018424 | Transplantation | Primary Myelofibrosis | Homologous | Janus Kinase 1
Journal Article
Haematologica, ISSN 0390-6078, 05/2019, Volume 104, Issue 5, pp. 947 - 954
EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of... 
DEFINITION | JAK2 INHIBITOR | SYMPTOM ASSESSMENT FORM | EFFICACY | SAFETY | INCB018424 | OPEN-LABEL | QUALITY-OF-LIFE | SCORING SYSTEM | HEMATOLOGY | AVAILABLE THERAPY
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 04/2019, Volume 27, Issue 8, pp. 1562 - 1576
Janus kinases (JAKs) regulate various cancers and immune responses and are targets for the treatment of cancers and immune diseases. A new series of 1... 
Inhibitor | 1H-pyrazolo[3,4-d]pyrimidin-4-amino | JAK2 | Intramolecular hydrogen bond | POTENT | CHEMISTRY, MEDICINAL | EFFICACY | BIOCHEMISTRY & MOLECULAR BIOLOGY | MUTATION | CHEMISTRY, ORGANIC | INCB018424 | CANCER
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 02/2012, Volume 11, Issue 2, pp. 103 - 104
Journal Article
Cancer, ISSN 0008-543X, 02/2014, Volume 120, Issue 4, pp. 513 - 520
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2015, Volume 58, Issue 18, pp. 7596 - 7602
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 6, pp. 1202 - 1209
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2012, Volume 18, Issue 11, pp. 3008 - 3014
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 02/2018, Volume 128, Issue 2, pp. 789 - 804
Journal Article
Cancer Discovery, ISSN 2159-8274, 2015, Volume 5, Issue 3, pp. 316 - 331
Journal Article
American Journal of Physiology - Endocrinology And Metabolism, ISSN 0193-1849, 08/2012, Volume 303, Issue 3, pp. 410 - 421
Cachexia, the metabolic dysregulation leading to sustained loss of muscle and adipose tissue, is a devastating complication of cancer and other chronic... 
Signal transducer and activator of transcription | Incb018424 | Electroporation | Inhibitory peptide | T cell protein tyrosine p